SUNPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 57/100 — Quality 79 · Valuation 23 · Growth 62 · Momentum 50
| Share price | ₹1,956.40 |
| Market cap | ₹4.17 lakh Cr |
| P/E ratio | 38.2 |
| P/B ratio | 5.4 |
| ROE | 18.8% |
| ROCE | 18.9% |
| Dividend yield | 0.95% |
| Book value | ₹324.46 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹58,462 Cr | ₹11,509 Cr | 28.0% |
| 2025 | ₹52,578 Cr | ₹10,965 Cr | 29.0% |
| 2024 | ₹48,497 Cr | ₹9,610 Cr | 27.0% |
| 2023 | ₹43,886 Cr | ₹8,513 Cr | 27.0% |
| 2022 | ₹38,654 Cr | ₹3,389 Cr | 27.0% |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides g